Contents
On Friday, December 17, an oral drug for COVID-19 was delivered to Poland. At the moment, 5 thousand are available in our country. tablets. Molnupiravir is not yet fully approved by the European Medicines Agency (EMA), but has received positive recommendations. The drug has also been administered in Denmark since December 16.
- Molnupiravir could be a breakthrough in the treatment of COVID-19
- It is the first oral drug that can be taken by patients to protect against hospitalization (another available drug, remdesivir, is used in patients with severe infections)
- Due to the small pool of molnupiravir, it will first go to those infected with comorbidities
- More information can be found on the Onet homepage
The drug for COVID-19 is already in Poland. It reduces the risk of hospitalization
Later this week, the first patients in Poland will receive molnupiravir – an oral drug against COVID-19. On Friday, December 17, our country received 5 thousand. pieces of preparation that are supposed to reduce the risk of hospitalization among those infected with coronavirus.
Molnupiravir is to be first intended for patients with comorbidities.
– Due to the small amounts of the tablets, the tablets will be first transferred to oncology and hemato-oncology hospitals, dialysis centers and transplant centers. It is a drug that was supposed to be a breakthrough for two reasons: it is given in tablets and is to prevent a hospital stay (due to COVID-19), i.e. it is to have a preventive effect. It is a drug that has not been fully approved by the European Medicines Agency, but has received positive recommendations. The EMA has decided that it allows the preparation to be used and recommends it to patients in the first five days of the disease, says the representative of the Polish government in «DGP».
- Also check: Omikron «goes crazy in the world». What about Christmas? Experts tell you what to do
Clinical trials on the drug initially indicated that it provides about 50 percent. protection against hospitalization among coronavirus patients. The final results showed, however, that the effectiveness is lower and reaches approx. 30%.
The rest of the text is below the video.
Molnupiravir – for whom?
Molnupiravir is to be given to people infected with the coronavirus who do not require oxygen therapy but are at risk of developing the infection with a severe course. Contraindication to taking this drug is pregnancy, as well as planning motherhood in the near future. At the same time, women of childbearing potential who are going to take molnupiravir must use effective contraception while taking the drug, and for four days after stopping treatment. Animal studies have shown that high doses of molnupiravir may affect fetal growth and development.
Among the possible side effects of the drug, the most common were diarrhea, nausea, dizziness, and headache, all of which were mild to moderate.
- Editors recommend: Omikron also poses a threat to children. Expert alerts: if your child has these symptoms, get a COVID-19 test
How is the COVID-19 drug administered?
Molnupiravir is an antiviral medicine that works by blocking the reproduction of SARS-CoV-2 virus. This, in turn, may result in a milder course of the disease.
The drug in the form of capsules is to be administered orally at an early stage of infection (within the first five days of infection). There are two doses per day to be used continuously for five days.
Poland among the first countries to use molnupiravir
The effectiveness of molnupiravir in clinical trials was approximately 30%. The drug has not yet been fully approved by the European Medicines Agency. Denmark was the first in the European Union to use molnupiravir.
– We recommend treatment with these pills because we believe that the benefits outweigh the side effects in patients who are most at risk of serious complications from COVID-19, said the representative of the Danish health agency Kirstine Moll Harboe in a statement.
The drug is already authorized in the UK. In turn, France decided not to authorize molnupiravir due to the low effectiveness of the preparation.
Do you want to test your COVID-19 immunity after vaccination? Have you been infected and want to check your antibody levels? See the COVID-19 immunity test package, which you will perform at Diagnostics network points.
Also read:
- How Much Does COVID-19 Treatment Cost At Home? Here is my kit
- This is how the coronavirus kills. The doctor tells you what “fails” in the body
- Dr. Fauci: The third dose protects against the Omicron. “The message remains clear”
- Doctor Cautions: Omikron and Delta May Create a New Coronavirus Super Variant
The content of the medTvoiLokony website is intended to improve, not replace, the contact between the Website User and their doctor. The website is intended for informational and educational purposes only. Before following the specialist knowledge, in particular medical advice, contained on our Website, you must consult a doctor. The Administrator does not bear any consequences resulting from the use of information contained on the Website. Do you need a medical consultation or an e-prescription? Go to halodoctor.pl, where you will get online help – quickly, safely and without leaving your home.